Background racial disparities in hypertension control are well documented, yet the contribution of providers to these disparities remains unclear. The objective of this study was to examine whether provider management of uncontrolled hypertension differed by patient race.
january 2010 | VOLuME 23 nuMBEr 1 | 54-61 | AMERICAN JOURNAL OF HYPERTENSION nature publishing group original contributions Racial disparities in cardiovascular disease are well documented, and hypertension is no exception. 1 National data reveal that black persons have a higher age-adjusted prevalence of hypertension than whites, but also greater hypertension awareness and treatment. 2 Nevertheless, black patients receiving treatment for hypertension are significantly less likely to have controlled blood pressure than white patients. [2] [3] [4] [5] These racial disparities in hypertension control likely contribute to the increased cardiovascular morbidity and mortality in the black population, including death and disability from strokes, end stage renal disease, and cardiac disease. [6] [7] [8] Many factors such as socioeconomic status, medication regimens, and cardiovascular comorbidities have been postulated as playing a role in this racial disparity in hypertension control. [3] [4] [5] [6] 9, 10 Additionally, a consensus statement by the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks (ISHIB) cited poor management by health-care providers as a "key obstacle" to hypertension control in black patients. 7 Indeed, at least one study found training deficiencies in physicians who treat black patients. 11 "Clinical inertia" by providers could also impact hypertension control between the races. As described in a recent editorial, "clinical inertia" represents the phenomenon where providers do not initiate or intensify therapy when clinically indicated. 12 One study found that providers intensify oral diabetes medications less often in their black patients with uncontrolled diabetes than white patients. 13 But few studies of antihypertensive medication intensification in patients with uncontrolled hypertension have found patient race to be a key predictor. 6, [14] [15] [16] [17] [18] [19] [20] [21] One exception is a recent study in a managed care organization that reported a similar or slightly greater likelihood of antihypertensive medication intensification at visits of nonwhite patients with uncontrolled hypertension when compared with white original contributions Racial Disparities in Hypertension Control patients. 22 Yet none of these studies have accounted for the potency of antihypertensive medication prescribed nor have these studies adjusted for a broad array of patient, provider and other health-care characteristics. In addition, these studies have not explored which of these characteristics contribute most to explaining observed disparities.
After accounting for this broad array of characteristics, we hypothesized that black patients would be more likely to have uncontrolled hypertension and, when uncontrolled, would less commonly have provider-initiated intensification of their antihypertensive medication regimen compared with white patients. Further, we expected to find that white providers would be less likely to intensify treatment for black as compared to white patients.
Methods
Study population and setting. We conducted a retrospective cohort study of hypertensive patients aged 18 or older with visits from1/2004 through 12/2006 to six urban primary care practices affiliated with an academic medical center in Philadelphia, Pennsylvania. Primary care practices included internal medicine clinics, as well as family medicine and geriatrics. Study patients were established in a study practice with ≥1 visit(s) after meeting criteria for hypertension. Subjects meeting criteria for hypertension had at least two of the following during the study time period: (i) International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for hypertension (401-404), (ii) elevated blood pressure, or (iii) prescribed antihypertensive medications. 23 We only analyzed patient visits that occurred after criteria for hypertension were met in the study time frame. We excluded 199 patients missing race, weight, comorbidities, or income (<0.01% of the initial study cohort of 20,856). We also excluded patients of providers with <100 patient visits annually, racial/ethnic groups other than black or white, and those with missing blood pressure or practice identifiers as described in Figure 1 .
All practices shared the same electronic medical record (EMR) including patient information on demographics, insurance, clinical diagnoses, laboratory data, prescribed medications, and visit attendance. All prescriptions were mandated to be entered into the EMR. One blood pressure measurement was entered into the vital signs record at each visit by a nursing assistant. Although there was only one completed blood pressure field per visit, the blood pressure field could be updated by clinicians with their own measurements at their discretion. Measurements listed as free text in the body of a progress note were not captured. The EMR also identified the provider and practice for each patient visit. For each study provider, we linked information on gender, race, and training level from internet, certification, and departmental sources. For each practice, we obtained staffing information.
Antihypertensive medication data. Antihypertensive medications were standardized into a generic form and grouped by strength. We excluded prescriptions with "as needed" or indications such as anxiety or edema. Combination antihypertensive medications were examined as their component drugs. The duration of a prescription was calculated as follows: ((number of prescribed pills)/(daily pill dose)) × (refill number). Daily dose was defined by the prescription. When a medication was reordered before completing the earlier prescription, the duration was recalculated from the start of the new prescription. A medication was judged to be no longer "active" when all refills were expended or a stop date entered.
Dependent variables. The two outcome variables for this study were: (i) uncontrolled hypertension in accordance with the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 24 and (ii) no intensification in hypertension treatment at a visit with uncontrolled hypertension. Following our earlier work, 23 no intensification was defined as provider failure to: (i) initiate a new antihypertensive medication, (ii) increase the dose of an existing antihypertensive medication, or (iii) renew an antihypertensive prescription expired >30 days before the patient visit. The 30-day window allowed the patient time to use up any left over medication from a completed prescription.
Independent variables. Patient race was defined by patient self-report at the time of practice registration. To evaluate the potency of the antihypertensive medication regimen prescribed prior to each visit, we followed the approach of Bailey et al. where the recorded daily dose of antihypertensive taken by the patient was divided by the maximum recommended daily dose to obtain a proportional dose for that medication. 25 Proportional doses were then summed across all medications. For example, if a patient were prescribed half the maximum dose of one antihypertensive medication, and the maximum dose of another, their treatment potency would be the sum of 0.5 and 1.0, or 1.5. 
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Health-care utilization variables included adherence to scheduled appointments, the number of office visits prior to the visit of interest, and the interval since the last attended office visit. Other patient variables were classified as: (i) demographics, (ii) health-care access variables including insurance type and median annual household income per zip code of residence, 26 and (iii) comorbidities defined from diagnosis codes and/or appropriate laboratory values as related to vascular disease (e.g., diabetes and chronic renal insufficiency) and unrelated (e.g., arthritis, asthma, depression). 23 We defined diabetes by the following criteria: (i) an ICD-9 diagnosis of diabetes (250.00) on more than one occasion; (ii) at least one hemoglobin A 1C ≥7.0; or (iii) a prescription for at least one diabetes medication. The definition of chronic renal insufficiency was any creatinine >1.5 mg/dl. We also adjusted for the current and the immediately preceding visits' blood pressures in our analyses of the relationship between race and no intensification in hypertension treatment. To do this, we categorized blood pressure into: normotensive (the reference standard), stage 1, or stage 2 hypertension. Normotensive in patients with diabetes and/or chronic renal insufficiency was a systolic <130 mm Hg and a diastolic <80 mm Hg and in all other patients was a systolic <140 mm Hg and a diastolic <90 mm Hg. Stage 1 hypertension in patients with diabetes or renal insufficiency was a systolic 130-159 mm Hg or a diastolic 80-99 mm Hg and in all other patients was a systolic 140-159 mm Hg or a diastolic 90-99 mm Hg. Stage 2 hypertension in all patients was a systolic >160 mm Hg or a diastolic >100 mm Hg.
Provider variables included provider type (i.e., attending, resident, nurse practitioner/physician's assistant), race/ethnicity, sex, and workload. Workload was calculated from scheduling records as the annual number of arrived patient visits per provider. 23 Practice variables included staffing characteristics of the six study practices, including nurses, administrative personnel, and other clinical staff (i.e., medical assistants, licensed practical nurses, and office social workers). For each group, we calculated the proportion of each staff type per 1,000 patient visits. Table 1 offers a complete list of the variables included in the study.
To examine the relationship between provider-patient race and intensification of blood pressure treatment, we categorized visits into six provider-patient race categories, and then measured the association of those different categories with our outcome, adjusting for all variables except the independent variables representing patient and provider race. The six categories included: (i) visits with a white provider-white patient (the reference standard), (ii) visits with a white providerblack patient, (iii) visits with a black provider-black patient, (iv) visits with a black provider-white patient, (v) visits with an asian provider-white patient, and (vi) visits with an asian provider-black patient.
Data analysis. χ 2 and t-tests were used to assess the statistical significance of differences in the baseline characteristics of black vs. white patients at their first visit in the study time frame after the patient met the above criteria for hypertension. We also estimated the average systolic and diastolic blood pressures for black vs. white patients across all visits, as well as the average intensities of antihypertensive medication regimens, and assessed statistical differences between black vs. white patients using parametric and nonparametric tests as appropriate.
Sets of variables (see Table 1 ) were added sequentially to models to observe their effect on the association of black race with the outcome of interest. We fit the data using generalized estimating equations to account for clustering of visits within patients. Practice characteristics were modeled as fixed effects. Sensitivity analyses included fitting random effects logistic regression models that accounted for clustering of patients by provider, and including depression as an independent comorbidity in models adjusting for the effect of comorbidites on our outcomes of interest. We do not report the results of these analyses as they were consistent with the primary models reported in the results. Analyses were conducted using STATA 9.0 (STATA, College Station, TX) and SAS 9.1.3 (SAS, Cary, NC). Hypothesis tests were two tailed, using a P = 0.05 level of significance. The University of Pennsylvania Institutional Review Board approved the study.
results
Our study sample included 16,881 hypertensive patients with 132,730 visits during the study time frame (Figure 1) . For all visits, the average systolic and diastolic blood pressures for Table 2) . In regard to health-care access, black patients were more likely than whites to be insured by Medicaid. Black patients were less adherent to attending visits than white patients, but had a similar time interval between visits that they did attend. Both cardiovascular and noncardiovascular comorbidities were more prevalent in black than white patients. Black patients' blood pressures were more likely to be elevated at the current and immediately preceding visits. Black patients were prescribed more antihypertensive medications than white patients. In addition, the mean potency of antihypertensive medications at visits during the study time frame was 0.86 (s.d. 0.87) for black patients vs. 0.48 (s.d. 0.l6) for white patients (P < 0.001). The providers treating black patients were more likely to be racial/ethnic minority, female, and residents. Practice nurse staffing was similar for black and white patients but other staffing ratios differed, in particular black patients were seen in practices with fewer administrative staff. The blood pressure was uncontrolled at 50.0% of study visits but more often at visits of black as compared to white patients (55.3% vs. 43.4%, P < 0.001). In an unadjusted model, black race was associated with more than a 60% higher odds of uncontrolled hypertension compared with white race ( Table 3 ). In models that adjust separately for each set of potential explanatory variables, comorbidities, blood pressure, and health-care access variables showed the greatest moderating effects on the association of race with the outcome. However, after full adjustment, the odds of uncontrolled hypertension were still 40% higher for black compared with white race.
Among visits with uncontrolled hypertension (N = 66,327), no intensification of antihypertensive treatment occurred less frequently at the visits of black compared with white patients (67.9% vs. 72.2%, respectively, P < 0.001); the unadjusted odds of no treatment intensification was 20% lower for black than white visits ( Table 4) . Models examining each set of potential explanatory variables show that health-care access, provider characteristics, and blood pressure variables, including antihypertensive medication potency, had the greatest moderating effects on the protective association of black race with the outcome. After adjustment for all variables, the association of black race with the outcome remained statistically significant, but the effect size was smaller.
We also examined the effect of concordant and discordant patient and provider race with no intensification of antihypertensive medication for uncontrolled hypertension. Compared with a white provider treating a white patient, the odds of no intensification of treatment were significantly higher for black provider-black patient (1.24 (confidence interval (CI) 1.15-1.34)), asian provider-white patient (1.62 (CI 1.38-1.90)), and asian provider-black patient (1.10 (CI 1.01-1.20)), but not for In this cohort of urban primary care patients, black race when compared with white race was associated with 40% higher odds of having uncontrolled hypertension, and a marginally higher odds of having antihypertensive medications intensified when blood pressure was uncontrolled.
Although data from the National Health and Nutrition Examination Survey from earlier in this decade showed that blood pressure control had improved in black patients compared with the prior decade, the gap in blood pressure control between blacks and whites who are receiving treatment continues to increase. 2 Cohort studies have reported a similar increase in the adjusted odds of uncontrolled hypertension for black vs. white patients. 5 Even randomized trials where care is largely standardized, such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, have found that black patients have a 25% lower adjusted odds of controlled hypertension after 3 years of follow-up compared with nonblack patients. 4 Deficiencies in provider management of uncontrolled hypertension are a logical concern that could contribute to poorer blood pressure control among black patients in medical care. However, we found less provider "clinical inertia" with regard to antihypertensive medication intensification for their black as compared to their white patients. Contrary to our hypothesis, black patients had 20% lower unadjusted odds of no intensification in antihypertensive treatment at visits with uncontrolled hypertension, and this association was still protective after full adjustment. This adjustment accounted for many of the most important determinants of antihypertensive treatment intensification identified in the literature, including the severity of blood pressure elevation 14, 17, 19, 21 and the potency of antihypertensive medication treatment. 19 Despite the increased odds of therapy intensification for black patients in our study, less potent treatment regimens could theoretically explain their poorer blood pressure control. However, we found that black patients were prescribed more potent medication regimens than white patients, and we adjusted for antihypertensive treatment potency in our analyses. Other medication-related factors that we could not assess may affect achievement of control. For example, black patients have been reported to have more side effects from certain antihypertensive drugs, 27 which may limit the use of more effective regimens.
Our results complement evidence suggesting that black patients are more likely to receive treatment for hypertension than white patients, 2 that black patients' providers are more active in advising about hypertension care, 28 and that physicians employ pharmacological means to control hypertension more often in nonwhite patients. 22 These findings may reflect physician concern about hypertension and the difficulty of achieving hypertension control in black patients. Other studies have not found that physicians are more aggressively managing their black patients, but these studies are limited by their smaller sample sizes and more homogenous patient populations, and many did not specifically examine race. 6, [14] [15] [16] [17] [18] [19] [20] [21] Quality of care for black patients may have other deficiencies. For example, it is possible that providers should be focusing more on medication adherence instead of medication changes. 29 Medication adherence has been reported to differ between black and white patients and is associated with hypertension control. 30 We attempted to adjust for medication adherence in our analyses by using the surrogate "adherence to scheduled appointments. " 31 In a separate analysis only in black patients, we found that high appointment adherence was associated with improved blood pressure control, suggesting that appointment adherence may be a proxy for medication adherence. Other patient-level factors that we did not examine and may negatively affect blood pressure control include diet, 6, 7, 32 physical activity, 6, 7, 32, 33 physiology, 6 genetics, 6 psychosocial stressors, 34, 35 and concomitant use of certain medicines like steroids and decongestants. 36 Cooper also described the critical role of the patients' cognitive, affective and attitudinal characteristics as well as the patient-physician relationship in hypertension control. 37 These factors are difficult to measure but we did attempt to adjust for some of these relationship dynamics by examining the association of provider-patient race discordance with management of uncontrolled hypertension. Compared with white providers treating white patients, Asian, or black providers were significantly less likely to intensify treatment in their black patients whereas white providers did not differ. In addition, black providers treating white patients did not differ significantly from white providers treating white patients. Thus, racial discordance does not seem consistently associated with inferior or superior medical management of uncontrolled hypertension.
Adjustment for comorbidities had the strongest effect on reducing the association between black race and uncontrolled hypertension. Black patients had significantly greater prevalence than white patients of comorbidities that indicate the need for a lower blood pressure control standard including diabetes and chronic renal insufficiency; failure to achieve this strict standard may account in part for poorer control in black patients. Adjustment for variables related to health-care access, provider characteristics and blood pressure variables, including antihypertensive medication potency, had the greatest moderating effects on the protective association of black race with no intensification of treatment. Given that black patients in our study had higher blood pressure severity and antihypertensive medication potency, and that these variables have been associated with an increase in antihypertensive medication intensification in past studies, 14, 17, 19, 21 it makes sense that adjusting for these variables would decrease the protective association of black race with no intensification of antihypertensive therapy.
Our study had a number of limitations. First, the study practices were affiliated with one academic health system, so generalizability may be limited. However, these practices care for a diverse group of patients typical of large urban and suburban practices. Second, our definition of intensification of antihypertensive medication did not account for potentially appropriate provider actions such as rechecking blood pressure measurements and finding them to be normal. Our definition also did not evaluate counseling by physicians for those with identified medication nonadherence. When patients do not adhere to their medication regimens, we would expect less "intensification of medical therapy, " because counseling about adherence would be the more appropriate action. Based on our measure of visit adherence as well as prior research, 30 we would have expected black patients in our study to have less medication adherence, resulting in more counseling about adherence and thus less "intensification of medical therapy. " But because we found that black patients were more likely to have their medications "intensified, " this argues against identified poor adherence as a cause for the observed racial differences in "intensification, " and suggests that not adequately adjusting for medication adherence would have biased our results to the null. Another limitation to our definition of medication intensification is that it did not account for the adequacy of medication intensification by providers. For example, we don't know whether patients with renal insufficiency were more likely to receive ace inhibitors rather than thiazide diuretics. However, we do know that black patients in general had a higher number of antihypertensives and a higher antihypertensive medication potency as compared to white patients. Third, the prescribed medications in the EMR may not have been accurate. However, our providers were required to enter all prescribed medications into the record and a Veterans Administration study found that current antihypertensive medications were omitted in <2% of EMRs. 38 As this was not an inception cohort, we also did not know how long subjects had hypertension before entering the study. Because titration of blood pressure original contributions
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medications routinely occurs in the first months of therapy, if both the races had a higher proportion of newly diagnosed patients, then they might be more likely to be in the titration phase and more likely to have their antihypertensive medications intensified. However, given that black patients overall were on more antihypertensive drugs than white patients at their first study visit, this suggests that black patients were less likely to have newly diagnosed hypertension as compared to white patients, and would bias our results to the null. Finally, we used blood pressure measurements recorded in the EMR instead of standardized measurements typical of clinical trials. However, satisfactory agreement between standardized measurements and clinic-based systolic and diastolic blood pressures has been described. 39 Putting racial differences in blood pressure control aside, it is important to note that a large number of both black and white patients in this cohort had poor blood pressure control, and that there are great opportunities for blood pressure improvement in many of these patients. Similarly, the majority of patients with uncontrolled hypertension had no intensification of treatment, regardless of race. This is reflected by the low average antihypertensive medication potency in the two groups.
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